TGF-β-receptor ectodomain fusion molecules and uses thereof
US11866481B2 · kind B2 · utility
0Cited by
7References
43Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Mar 1, 2018 |
| Grant date | Jan 9, 2024 |
| Priority date | — |
| Expiry date | Dec 16, 2038 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07K2319/30
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The present invention relates, in general, to polypeptides capable of binding and neutralizing transforming growth factor beta (TGF-β) ligands, and uses of these polypeptides for treating disorders related to TGF-beta expression or activation (e.g. cancer and fibrotic diseases), and methods of making such molecules.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.